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Abstract
Merkel Cell Polyomavirus (MCV) is a common infectious agent likely to be involved in the pathogenesis of most Merkel cell
carcinomas (MCC). Trichodysplasia spinulosa-associated polyomavirus (TSV), which exhibit high seroprevalence in general
population, has been detected in trichodysplasia spinulosa (TS) skin lesions suggesting an etiological role for this disease.
Previous studies have shown strong MCV-specific T-cell responses, while no data exist on T-cell immunity against TSV. In
order to characterize Th-cell immunity against TSV, and to allow comparisons with the MCV-specific Th-cell immunity, we
studied TSV-specific proliferation, IFN-c, IL-10 and IL-13, and MCV-specific IFN-c and IL-10 responses in 51 healthy
volunteers, and in one MCC patient. Recombinant TSV and MCV VP1 virus-like particles (VLPs) were used as antigens. A
significant correlation was found between virus-specific Th-cell and antibody responses with TSV; with MCV it proved
weaker. Despite significant homology in amino acid sequences, Th-cell crossreactivity was not evident between these
viruses. Some subjects seronegative to both TSV and MCV exhibited Th-cell responses to both viruses. The agent initially
priming these Th-cells remains an enigma. As CD8+ cells specific to MCV T-Ag oncoprotein clearly provide an important
defense against established MCC, the MCV VP1-specific Th-cells may, by suppressing MCV replication with antiviral
cytokines such as IFN-c, significantly contribute to preventing the full process of oncogenesis.
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Introduction
Polyomaviruses are small, non-enveloped double stranded DNA
viruses. In 2008, Feng et al. discovered a new polyomavirus,
Merkel cell polyomavirus (MCV) accounting for most cases of
Merkel cell carcinoma (MCC), an aggressive neuroendrocrine
cancer of the skin [1,2]. Clonally integrated into the MCC
genome, the viral sequences have been shown to be present in 24–
89% of MCC tumors worldwide, [3–8]. HPyV6 and HPyV7, two
human polyomaviruses newly discovered, also seem to have a
predilection for the skin. Serological studies have demonstrated
infections by these three dermatotropic polyomaviruses to be very
common [9–13].
A new polyomavirus, TSV, was recently identified in an
immunosuppressed individual with this rare, severe skin disease,
trichodysplasia spinulosa (TS) [14]. This disease is characterized by
spicules, i.e. follicular papules and keratin spines that become
widespread on the face, sometimes accompanied by alopecia of the
eyebrows and lashes, and, in some cases, leading to facial
distortion. Histopathology of the affected skin showed distended
and abnormally matured hair follicles with high numbers of inner
root sheath cells containing excessive amounts of trichohyalin
features. Electron microscopic studies revealed the presence of
polyomavirus-like particles in skin biopsies of TS patients, which
accords with the etiological role of TSV for this disease [15–20].
Even if infections by TSV occur frequently, they appear to become
symptomatic only in immunocompromised patients. The existing
data indicate that TSV infections are frequent among the general
population (, 70% seroprevalance), and that primary infection
often occurs in childhood [21,22].
CD4+ cells play important roles in antiviral immunity by
producing antiviral cytokines, providing help for B cells in
antibody production, as well as generating cytotoxic and memory
CD8+ T-cell populations. Recent studies have defined additional
functions for CD4+ T-cells in enhancing innate immune responses
and mediating non-helper antiviral effector functions [23,24]. We
and a few others have recently shown T-cells to be important
mediators of MCV-specific immune surveillance [25,26].
In this study we compared the characteristics of Th-cell
immunity with the two dermatotropic human polyomaviruses,
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MCV and TSV. We investigated proliferation, IFN-c IL-10, and
IL-13 cytokine responses by stimulating PBMC with MCV or
TSV VP1 virus-like particles (VLP). IFN-c is an archetype II
interferon [27] which has direct antiviral activity, enhancing
cellular cytotoxicity, and acting as a critical extrinsic tumor-
suppressor factor in immunocompetent hosts via several types of
antitumor actions. While Th1-cells predominantly produce IFN-c,
also cytotoxic T-cells and NK cells give rise to this proinflamma-
tory cytokine [27–31]. A therapeutic effect of type I and II IFNs on
MCV-positive MCC cell lines has been shown recently [32].
IL-10 has potent immunosuppressive effects and serves a
substantial role in the regulation of immune responses. Its major
sources are Th-cells and a subset of regulatory T-cells. IL-10
inhibits Th1 cells, NK cells and macrophages. These three cell
types are required for optimal pathogen clearance, and they also
contribute to tissue damage during infection. In consequence, IL-
10 can both impede pathogen clearance and ameliorate immu-
nopathology [33,34]. Besides these functions IL-10 also induces B-
cell growth and IgG secretion, and is essential for the maintenance
of the human germinal centre B-cells in vitro [35].
IL-13 is an important cytokine produced mainly by Th2 cells
[36]. It has several unique effector functions including the
regulation of gastrointestinal parasite expulsion, intracellular
parasitism, airway hyperresponsiveness, allergic inflammation,
and the class switch to IgE and IgG4 [37,38]. In many studies
IL-13 is suggested to have a contradictory role in tumor immunity
[39–41].
To characterize the Th-cell immunity against TSV, and to
allow comparisons to MCV-specific Th-cell immunity, we studied
MCV and TSV-specific proliferation, IFN-c IL-10 and IL-13
responses. As TSV and MCV VP1 are known to have significant
structural similarities [14], we wanted to investigate whether it is
possible to distinguish one Th-cell response from another.
Materials and Methods
Study Groups
Altogether 51 randomly selected healthy asymptomatic subjects,
with no underlying diseases were studied: 30 were seropositive (15
men, 15 women, aged 19–58 years) and 21 seronegative (5 men,
16 women, aged 20–58 years) for TSV and 24 (8 men, 16 women,
aged 19–58 years) and 27 (12 men, 15 women, aged 20–58 years)
for MCV, respectively. The study protocol followed the human
experimentation guidelines of the US Department of Health and
Human Services in the conduct of clinical research and was
approved by the ethics committee of the Department of Medicine
at Helsinki University Central Hospital. Written informed consent
was obtained from all volunteers.
MCV and TSV-specific Th-cell responses were also studied in a
48-year old MCC patient. The patient was HIV negative, and had
no immunosuppressive medication or other known immunodefi-
cencies. The tumor biopsies of skin and blood samples were
analyzed by quantitative PCRs for MCV [42] and TSV [14]
DNAs and by cytokine assays. Clinical data of this patient are
enclosed as supplement (Note S1).
Antigens for Proliferation and Cytokine Assays
The major capsid protein, virus protein (VP) 1 of MCV and
TSV were expressed with recombinant baculoviruses in Sf9 cells
and purified by CsCl gradient ultracentrifugation as described
[22,43]. After extensive dialysis the protein was concentrated and
purified further with 50 KDa MWCO centrifugal filters (Amicon
Ultra, Millipore, Billerica, MA). The purities of antigens were
further characterized by silver staining (SilverXpress, Invitrogen,
Carlsbad, CA, USA) using same amounts of antigens, and by dot
blotting with seropositive human sera as described earlier
[22,25,43]. EM with negative staining VP1 of TSV showed
virus-like particles (Fig. 1). As a control antigen, we used in-house
prepared and heat inactivated Candida albicans. Endotoxin in the
antigen preparations was measured by the Limulus amebocyte
lysate assay (QCL-1000; Cambrex Biosciences, Walkersville, MD,
USA), and was less than 2 EU/mg with all the VLPs. Preparation
of the working stocks and analyses of MCV and TSV antigens
were carried out simultaneously.
Antibody Assays
We measured TSV and MCV IgG by enzyme immune assay
(EIA), employing as antigen virus-like particles as described
previously in detail [22,43]. For TSV, absorbance value .0.240
was determined as cutoff for being TSV IgG positive, whereas all
those with values ,0.100 were considered TSV IgG negative.
One of 51 samples showed an absorbance value between these
cutoffs. For this sample the TSV -VLP competition assay [22] was
performed, after which this sample was regarded as seronegative.
Isolation of PBMC
Blood was drawn to mononuclear cell separation tubes
(Vacutainer CPT, Becton Dickinson, Franklin Lakes, NJ, USA).
The tubes were centrifuged at 15006g for 30 minutes and washed
two times with PBS. PBMC were separated within 2 hrs of blood
sampling [44,45].
Lymphocyte Culture
Isolated PBMC were resuspended in RPMI-1640 (Sigma, St
Louis, MO, USA) containing 20mM HEPES, 2 mM L-glutamine,
streptomycin (100 mg/ml), penicillin (100 U/ml), 50 mM 2-mer-
captoethanol and 10% human AB serum (Cambrex Biosciences,
USA) and cultured at 37uC; 5% CO2 [25,44,45]. MCV and TSV
VLP were used at concentrations of 0.5 mg/ml and 1.5 mg/ml and
Candida albicans control antigen at 2.5 mg/ml.
Proliferation Assay
PBMC (200,000/well) were cultured with the antigens for six
days (37uC; 5% CO2) in triplicate in 96 well U-bottom plates
(Coster, Corning Inc., Corning, NY, USA) and pulsed for the last
16 hours with 1 m Ci of tritiated thymidine (specific activity 50 Ci/
mmol; Nycomed Amersham, Buckinghamshire, UK). Thymidine
Figure 1. Characterization of antigens. EM of sterile TSV particles
(A) purified by caesium chloride density gradient ultracentrifugation,
with 200 nm scale bar shown. Dot blotting (B) for TSV antigen, studied
with TSV-IgG positive (I) and negative (II) sera. Silver staining of capsid
proteins (C) in 10% SDS PAGE. Lane 1: TSV VP1 capsid antigen, lane 2:
MCV VP1 capsid antigen, lane 3: molecular weight markers.
doi:10.1371/journal.pone.0045773.g001
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incorporation was measured in a scintillation counter (Microbeta,
Wallac,Turku, Finland) [25,44,45]. The data were expressed as
counts per minute (D cpm): D cpm = mean cpm (test antigen) –
mean cpm (media).
Cytokine Assays
PBMC culture supernatants were harvested after 3 days for
IFN-c and after 5 days for IL-10 and IL-13, and were stored at
220uC. Cytokine production in the supernatants was analysed by
IFN-c, IL-10 (Pharmingen, San Diego, CA, USA) and IL-13
(Invitrogen corporation CA, USA) kits, according to the manu-
facturers’ instructions. Background (media) cytokine production
was subtracted from total to yield antigen specific cytokine
production [25,45]. The detection limits for IFN-c, IL-10 and
IL-13 were 5, 8 and 6 pg/ml, respectively.
Depletion of CD4+ or CD8+ Cells
PBMC were depleted of CD4+ or CD8+ T cells by using
magnetic beads coated with CD4- or CD8-specific monoclonal
antibodies (Invitrogen Dynal AS, Oslo, Norway), according to the
manufacturer’s instructions. Then, 200,000 pure CD4+ or CD8+
depleted cells were cultured with the antigens as described
previously [25]. Efficiency of the depletion was analyzed by flow
cytometry (Cyan, Beckman Coulter). The depleted PBMC were
stained with RPE, FITC and APC (DakoCytomation, Glostrup,
Denmark) labeled monoclonal antibodies for CD4, CD8 and CD3
T cells. CD3+ cells were 99% CD8+ and CD4+ after depletion of
CD4 and CD8 T cells, respectively.
Antibody Blocking Assays
Class restriction of the T-cell responses was further studied by
HLA class II-specific MAbs (HLA-DR, DP, DQ) (IgG2a, clone
Tu39; BD PharMingen), or isotype control MAb (IgG2a, clone
G155–178; BD PharMingen). Briefly, PBMC were cultured with
either HLA class II-specific or isotype control MAb and culture
supernatants were collected on days 3 and 5 for cytokines analysis.
These antibodies were used at 5 mg/ml, according to the
manufacturer’s instructions.
Statistical Methods
Responses among MCV and TSV seropositive and seronegative
subjects were compared by using the Mann-Whitney U test.
Paired responses were evaluated by using the Wilcoxon Signed
Rank test. The correlations were studied with Spearman’s
correlation. The distribution of responders against each antigen
was studied using Fisher’s Exact test. P values ,0.05 were
considered significant. All analyses were done with a SPSS
statistical program version 15.0.
Results
Comparison of TSV-specific Proliferation, IFN-c, IL-10 and
IL-13 Responses in the TSV-Seropositive and
Seronegative Subjects
Table 1 shows the comparisons of the TSV-specific prolifera-
tion, IFN-c, IL-10 and IL-13 responses among the 30 TSV-
seropositive and 21 seronegative subjects. TSV-specific IL-10
responses were similar in these two groups, whereas proliferation,
IFN-c and IL-13 responses appeared to be stronger among the
TSV-seropositive than -seronegative subjects. However, these
differences did not prove statistically significant (Table 1). Back-
ground proliferation and cytokine responses were low and similar
among TSV-seropositive and -seronegative subjects (Table 2).
Individual variation of TSV responses was extensive, causing
large standard deviations in both groups, yet all subjects showed
strong responses with the Candida albicans control antigen (Fig. 2).
Comparison of MCV-specific IFN-c and IL-10 Responses in
the MCV-seropositive and Seronegative Subjects
In contrast to findings with TSV, the MCV-specific IFN-c and
IL-10 cytokine responses were significantly higher in the 24 MCV-
seropositive than in the 27 MCV-seronegative subjects
(P,0.0001) whereas the responses with Candida albicans control
antigen were similar (P$0.250) (Table S1).
Identification of TSV-specific Cytokine Secreting Cells
PBMC were first depleted of either of CD4+ or CD8+ T cells by
using monoclonal antibodies attached to magnetic beads. Alto-
gether 3 subjects were studied, among them two were seropositive
(T66, T28) and one was a seronegative ‘‘top responder’’ (T27) for
TSV. TSV-specific IFN-c L-10 and IL-13 secretion was readily
detectable after depletion of CD8+ T cells, whereas the removal of
CD4+ T cells strongly reduced the responses among all the subjects
(Fig. 3).
Next, we studied the influence of class II-specific MAb (expected
to prevent antigen presentation) and its isotype-matched control
on Th-cell responses. TSV-specific cytokine responses were readily
detectable with the isotype control MAb, whereas the HLA class
II-specific MAb invariably reduced the responses (Fig. 4).
The Effect of TSV-specific Humoral Response on TSV-
specific Th-cell Responses
First we studied whether there would be a correlation between
the strength of TSV-specific humoral response, described as
optical density 6 1000 (OD61000) and the Th-cell mediated
responses (Fig. 5A). A significant positive correlation was found
between humoral response and TSV-specific proliferation
(P= 0.008), IFN-c (P = 0.007) and IL-10 (P= 0.002) in the
30 TSV seropositive subjects; with IL-13 the correlation did not
reach significance (P= 0.098). Data for IFN-c and IL-10 are
shown in Fig. 5A.
The effect of TSV-specific humoral responses on TSV-specific
Th-cell responses was further studied by dividing the 30 TSV
seropositive subjects into two groups of equal size (15 subjects)
according to their TSV-IgG ODs (Fig 5B): subjects in group A had
ODs under and those in group B had ODs above the median OD
(1720) of the 30 TSV seropositive subjects. Group A had TSV-
specific responses similar to that found in the seronegative
controls. In group B, by contrast, both the TSV-specific
proliferation (P= 0.007) and IFN-c (P = 0.013) responses were
stronger than in the seronegative controls (Fig. 5B); no difference
was found in the TSV-specific IL-10 (P= 0.125) and IL-13
(P= 0.062) responses, or responses with the Candida albicans control
antigen (P$0.283).
Unanticipatedly, TSV specific proliferation (P= 0.008), as well
as IFN-c (P = 0.007) and IL-10 responses (P = 0.002) were all
significantly stronger in group B than in group A. No significant
difference was found in IL-13 responses (P = 0.098); proliferation
and cytokine responses with the Candida albicans control antigen
were similar (P$0.251) in both groups. Data for IFN-c and IL-10
are shown in Fig. 5B.
The Effect of MCV-specific Humoral Response on MCV-
specific Th-cell Responses
With MCV the correlations between humoral (MCV IgG
ODx1000) and Th-cell responses were less evident among the 24
Th-Cell Immune Responses against TSV and MCV
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seropositive subjects, and the lowest P-value was 0.053 both with
IFN-c and IL-10 (Fig. S1A). MCV specific IFN-c responses were
higher among those with MCV-IgG levels above the median (874)
than among those with values under this limit, both at 0.5 and at
1.5 mg/ml antigen concentrations, P = 0.020 and 0.028, respec-
tively (Fig. S1A). These groups showed no differences in their
MCV-specific IL-10 responses, P$0.32 (Fig. S1A) or responses
with the Candida albicans control antigen (P$0.18) (data not
shown).
MCV-seropositive subjects with ODx1000 under the median
still showed significantly stronger IFN-c responses than those
found among the seronegative controls (P#0.022) at both antigen
concentrations, whereas with IL-10 the difference was significant
(P = 0.049) only at MCV-antigen concentration of 0.5 and
borderline (P= 0.056) at 1.5 mg/ml (Fig. S1B). No differences
were found with the Candida albicans control antigen (Data not
shown).
The Effect of MCV-serostatus on TSV-specific Th-cell
Responses
In order to study whether there is crossreactivity between MCV
and TSV, the subjects were divided in four groups according to
their serological responses (Table 3): MCV+TSV+, MCV2TSV+,
MCV2TSV2 and MCV+TSV2.
Comparisons of TSV-specific responses between group
MCV+TSV+ and group MCV2TSV+, showed that MCV
seropositivity caused no significant increases in TSV responses
(P$0.092). Likewise, comparisons between groups MCV2TSV2
and MCV+TSV2, showed no significant differences (P$0.132)
(data not shown). Responses in groups MCV+TSV+ and
MCV+TSV2 were also similar (P$0.093), (data not shown),
whereas significantly stronger TSV-specific proliferation, IFN-c
and IL-13 responses were detected in MCV+TSV+ than in
MCV2TSV2 group (Table 4). TSV-specific IL-10 responses
(Table 4) and those to Candica albicans control antigen were similar
in both groups, (P$0.18), (data not shown) respectively.
The Effect of TSV-serostatus on MCV-specific Th-cell
Responses
Strikingly, with the MCV antigen Th-cell responses were
stronger even in the MCV+TSV2 than in the MCV2TSV+control
group. Responses with Candida albicans antigen were similar in
these groups (P$0.312) (Table S2).
Comparison of MCV- and TSV-specific Th-cell Responses
in Sub-groups
Th-cell cross-reactivity between TSV and MCV was further
studied by comparing Th-cell mediated IFN-c and IL-10
responses against TSV and MCV antigens within each of the
groups MCV+TSV+, MCV2TSV+, MCV2TSV2 and
MCV+TSV2 (Table 3).
In group MCV+TSV+ and in group MCV2TSV2 the responses
with MCV and TSV antigens were similar (Table 4). Interestingly,
in group MCV2TSV+, TSV-specific IFN-c responses with TSV
antigen were significantly stronger than with MCV antigen at
1.5mg/mL concentration, and also almost significantly stronger at
0.5 mg/ml concentration, whereas the differences with IL-10
responses were less apparent (Table 3). Finally, in group
MCV+TSV2, IFN-c and IL-10 responses were significantly
stronger with MCV than with TSV at both antigen concentrations
(Table 3). In this group the MCV-specific IFN-c responses were
even stronger at 0.5 mg/ml concentration than the TSV antigen
specific responses at 1.5 mg/ml antigen concentration (P= 0.007)
(Table 3).
MCV and TSV Specific IFN-c and IL-10 Responses in the
MCC Patient
Th-cell mediated immune responses were studied in a subject
with Merkel cell carcinoma whose clinical details are shown in
Note S1. Similarly to the healthy controls in group MCV+TSV2
described above, also this patient was seropositive for MCV and
seronegative for TSV, and much stronger IFN-c and IL-10
responses were found with MCV than with TSV (Note S1). The
kinetics of his MCV-specific IL-10 response was similar to that in
Table 1. Comparison of TSV-specific proliferation and cytokine responses in 30 TSV seropositive and 21 seronegative subjects.
Proliferation DCPM ±SD IFN-c pg/ml±SD IL-10 pg/ml±SD
IL-13 pg/
ml±SD
Ag (TSV VP1) concentration ( mg/ml) 1.5 0.5 1.5 0.5 1.5 0.5 1.5
TSV seropositive 12092610796 7858610538 128.26163.8 126.46214.6 56.2692.8 25.3651.9 24.1629.1
TSV seronegative 711266508 343463583 75.3692.3 50.8676.9 52.2665.5 21.2632.4 14.3620.1
P 0.095 0.145 0.301 0.362 0.878 0.653 0.184
doi:10.1371/journal.pone.0045773.t001
Table 2. Comparison of background (Media) proliferation and cytokine responses among TSV-seropositive and seronegative
subjects.
Proliferation DCPM ±SD IFN-c pg/ml±SD IL-10 pg/ml±SD IL-13 pg/ml±SD
TSV seropositive 10476794 3.467.2 7.664.4 1.363.6
TSV seronegative 125061468 4.366.0 9.064.8 0.361.7
P 0.989 0.346 0.326 0.307
doi:10.1371/journal.pone.0045773.t002
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healthy controls (5d response higher than 3d response); with TSV-
antigen a reverse pattern was detected (Note S1).
Discussion
Immune responses to viruses associated with cancer may reveal
valuable information on the pathogenesis of these diseases.
Cellular arm of immunity appears elemental in preventing both
TSV and MCV-mediated diseases, as immunosuppression predis-
poses to diseases associated with these viruses, trichodysplasia
spinulosa and MCC, respectively. The presence of MCV-specific
antibodies does not prevent the development of MCC [10,46].
However, in a recent study using synthetic peptides as antigens it
was shown that MCC tumors ultimately develop despite the
presence of intra tumor CD8+ cells specific for MCV T-Ag
oncoprotein [26]. Several immune evasion mechanisms were
proposed to explain this: low expression of MHC I in MCC,
defective homing or effector functions of CD8+ T cells or
induction of regulatory-like CD4+ T cells which might promote
tumor growth [26]. Respective data are not available on TSV.
The present study is the first to describe TSV-specific cellular
immunity. T-cell subset depletion and antibody blocking exper-
iments showed that TSV-specific responses were mediated by
CD4+ Th-cells. Moreover, the comparisons between TSV- and
MCV-specific responses further extend the knowledge about
MCV-specific Th- cell immunity. Besides helping B-cell immunity
and providing antiviral cytokines, Th-cells are essential for
generation of memory CD8+ T-cells [24,47,48]. In humans, also
the secondary activation of memory CD8+ T cells has shown to be
Th-cell dependent, and importantly, Th- and cytotoxic cells can
recognize different antigens during this process [49]. Therefore, it
appears likely that upon simultaneous presentation of T-cell
epitopes from both VP1 and LT -proteins, the VP1 protein-
specific Th-cells described here may also provide help for cytotoxic
(CD8+) T-cells recognizing epitopes within the nonstructural (LT)
proteins, [49].
Figure 2. Correlation between TSV VP1 and Candida albicans-
specific IFN-c responses. Correlation analysis between TSV VP1 and
Candida albicans-specific IFN-c responses were analysed among TSV-
seropositive (A) and seronegative (B) individuals.
doi:10.1371/journal.pone.0045773.g002
Figure 3. TSV VP1-specific T-cell responses after T-cell subset depletion. PBMC of two TSV seropositive (T66, T28) and one seronegative
subject were deplete either of CD4+ or CD8+ T cells and stimulated with TSV VP1-VLPs (1.5mg/ml). IFN-c (A), IL-10 (B) and IL-13 (C) were studied by
ELISA.
doi:10.1371/journal.pone.0045773.g003
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Highly purified virus-like particles (VLPs) were used as antigens.
Similarly to proteins from infectious viruses, also the VLP-derived
proteins need prior processing to antigenic peptides by the antigen
presenting cells. This is a major difference to approaches using
exogenous synthetic peptides, which bypass this initial step of
antigen processing, and therefore, are less natural antigens.
However, peptides are optimal tools for T-cell epitope mapping.
TSV-specific Th-cell responses did not differ significantly
between virus-seropositive and seronegative subjects, albeit the
average TSV-specific Th-cell responses were higher among the
TSV seropositives than the seronegatives. The presence of TSV-
seronegative responders may not fully explain this finding, as
respective MCV-seronegative responders were also detectable with
the MCV-antigen. Interestingly, however, the vigour of TSV-
specific humoral responses had a significant impact on TSV-
specific Th-cell responses, and subjects with highest antibody
responses not only had significantly stronger responses than the
seronegative controls, but also significantly stronger responses than
the TSV-seropositive subjects with lower TSV-specific IgG level.
At least two different things could account for this. First, subjects
with lower TSV-IgG and Th-cell response level may have
contracted the TSV infection long time before the subjects with
stronger responses became infected. Consistent with this, antibody
and Th-cell responses are known to decline with time [50]. Second
and more interesting explanation is that subjects with higher TSV-
specific responses could have had more reactivations or even
reinfections, each having a potential to boost both humoral and
cellular responses [51].
An association between virus specific Th-cell responses and
antibody responses was found also with MCV, yet it was less
evident than with TSV. In contrast to TSV, MCV-specific
cytokine responses were significantly stronger in the MCV-
seropositive than seronegative subjects, even when MCV+TSV2
and TSV+MCV2 subjects were compared.
Data from subgroup experiments showed that if there is any
crossreactivity between TSV and MCV, it must be relatively low,
since the MCV-serostatus had a significant impact on TSV-
specific responses only when double (TSV+ MCV+) seropositive
subjects were compared with double (TSV2MCV2) seronegative
subjects. Furthermore, some of these double seronegatives showed
significant Th-cell responses to both viruses, despite being
seronegative to both. This could imply that B-cell immunity
against these antigens would persist a shorter time than T cell
immunity, or that VP1 proteins of MCV and TSV would contain
Th-cell epitopes crossreactive with some other agents, such as
other human polyomaviruses (Table S3). Because a high level of
cross-reactivity is an essential feature of the T-cell receptor, it is
also possible that the Th-cells of our seronegative subjects had
originally been primed by Th-cell epitopes differing largely in
sequence from the MCV or TSV VP1 proteins [52–55]. The most
interesting possibility is that in some subjects MCV and/or TSV
infection induces cytotoxic CD4+ cells which would kill antigen-
presenting B-cells and cause eradication of virus specific antibody
response [56,57]. With the (MCV+TSV2) MCC patient an early
and exceptionally strong IL-10 response was detected with TSV-
antigen, suggesting that T-cell epitopes within TSV were
recognized as altered peptide ligands [58] or alternatively, these
common epitopes activated regulatory T-cells in this patient [59].
In both cases an IL-10 oriented T-cell response is known to occur
[58,59].
Taken together, Th-cell immunity appears to be much better
maintained against the major structural protein (VP1) of MCV
than TSV. As TSV and MCV infections appear to occur around
same age [21,22,43], the time span from the primary infection
should not explain this. Possibly MCV becomes reactivated in the
human body more readily than TSV, boosting Th-cell immunity
more efficiently. Comparison of TSV and MCV responses within
the MCV+TSV2 subjects (including the MCC patient) and within
the TSV+MCV2 subjects clearly showed that VP1 proteins from
both viruses contain unique Th-cell epitopes which are not shared.
However, as the differences between MCV and TSV responses
were more significant in the MCV+TSV2 than the TSV+MCV2
Figure 4. Effect of HLA class II-specific monoclonal antibodies on TSV-VP1 specific cytokine responses. PBMC of TSV seropositive
individuals were incubated with HLA class II-specific monoclonal antibody and with a isotype-matched contol antibody (MAbs) and stimulated with
TSV-VP1 for IFN-c (A), IL-10 (B) and IL-13 (C) assessment.
doi:10.1371/journal.pone.0045773.g004
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group, MCV VP1 appears to contain more unique virus specific
epitopes than TSV-VP1 does. Alternatively, Th-cell epitopes
within MCV VP1 have higher affinity for MHC II than Th-cell
epitopes of TSV VP1.
Figure 5. (A) Effect of TSV-specific IgG level on Th-cell responses. TSV-specific IFN-c and IL-10 responses were plotted against TSV-IgG
among seropositive (open circles) and seronegative individuals (closed circles). TSV VP1 specific humoral immune response is shown by optical
density61000 (OD61000). Median OD61000 (1720) is shown by (–) a line. (B) TSV-specific IFN-c and IL-10 responses were compared between the
TSV- seronegative subjects and sub-groups of TSV-seropositive subjects. Group A: TSV-seropositive subjects having TSV-IgG OD61000 below 1720,
and group B: subjects having TSV-IgG OD61000 above 1720.
doi:10.1371/journal.pone.0045773.g005
Table 3. Comparison of MCV and TSV-specific IFN-c and IL-10 (pg/ml6SD) responses in the different groups (responses at 0.5 m g/
ml concentration are shown in parentheses below responses at 1.5 m g/ml).
Serostatus IFN-c IL10
Group MCV TSV MCV TSV P MCV TSV P
1 Pos Pos 145.56190.9 117.6699.1 0.860 56.5647.3 54.5658.6 0.906
(114.06150.9) (101.76140.3) (0.701) (33.1625.3) (23.0618.2) (0.147)
2 Neg Pos 43.2658.0 136.36202.8 0.007 21.8 618.8 57.6 6114.3 0.270
(30.5645.3) (145.26260.5 (0.086) (11.6615.8) (27.1669.0) (0.687)
3 Neg Neg 44.6648.9 76.36106.2 0.860 40.3649.8 56.6685.5 0.670
(26.4635.7) (33.3668.0) (0.767) (16.7624.2) (22.2643.8) (0.233)
4 Pos Neg 179.86168.2 74.5683.1 0.003 120.0 6144.0 48.4 644.4 0.004
(189.86173.2) (66.8684.1) (0.003) (56.0631.9) (20.3621.5) (0.005)
doi:10.1371/journal.pone.0045773.t003
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Finally, as CD8+ cells specific for MCV T-Ag oncoprotein
clearly provide an important defence against established MCC
[26], the MCV VP1-specific Th-cells may be important in
preventing the full process of oncogenesis, by suppressing MCV
replication with antiviral cytokines such as IFN-c. If this
mechanism exists, also the MCV-crossreactive Th-cells should
have a cross-protective role, and subjects with these cells might be
less susceptible to develop MCC.
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